Serious harms of the COVID-19 vaccines: a systematic review
Gotzsche, P. C.; Demasi, M.
Show abstract
BACKGROUNDSerious and severe harms of the COVID-19 vaccines have been downplayed or deliberately excluded by the study sponsors in high impact medical journals. METHODSSystematic review of papers with data on serious adverse events (SAEs) associated with a COVID-19 vaccine. RESULTSWe included 18 systematic reviews, 14 randomised trials, and 34 other studies with a control group. Most studies were of poor quality. A systematic review of regulatory data on the two pivotal trials of the mRNA vaccines found significantly more SAEs of special interest with the vaccines compared to placebo, and the excess risk was considerably larger than the benefit, the risk of hospitalisation. The adenovirus vector vaccines increased the risk of venous thrombosis and thrombocytopenia, and the mRNA-based vaccines increased the risk of myocarditis, with a mortality of about 1-2 per 200 cases. We found evidence of serious neurological harms, including Bells palsy, Guillain-Barre syndrome, myasthenic disorder and stroke, which are likely due to an autoimmune reaction. Severe harms, i.e. those that prevent daily activities, were underreported in the randomised trials. These harms were very common in studies of booster doses after a full vaccination and in a study of vaccination of previously infected people. CONCLUSIONSFurther randomised trials are needed. Authorities have recommended populationwide COVID-19 vaccination and booster doses. They do not consider that the balance between benefits and harms becomes negative in low-risk groups such as children and people who have already recovered from COVID-19 infection.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course 95%
- Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study 94%
- Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England 93%
Similar papers in this journal
- Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021 94%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 94%
- The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan 94%
Similar papers in this journal
- Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S. 95%
- Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials 94%
- Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older 93%
Similar papers in this journal
- COVID-19 vaccines and evidence-based medicine 95%
- COVID-19 vaccination effectiveness rates by week and sources of bias 94%
- Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature 93%
Similar papers in this journal
- Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval 94%
- Intradermal versus Intramuscular Administration of Influenza Vaccination: Rapid Review and Meta-analysis 93%
- Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort Study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.